US pharmaceutical giant Aberdeen's US $55 billion acquisition of shire

Source: Tencent finance, July 21, 2014, Beijing time, July 18, evening news, abbvie, the US pharmaceutical company, finally reached 32 billion pounds (54.7 billion US dollars) with Dublin's shire, a British pharmaceutical company, on July 18, local time The deal will be a classic case for US companies to reduce taxes by acquiring UK companies in reverse The London listed company has been grappling with four previous acquisitions by Aberdeen until the latter raised its offer to £ 52.48 a share, including £ 24.44 in cash plus 0.896 new shares of Aberdeen Aberdeen acquired shire mainly to reduce the tax bill in the United States and its dependence on its best-selling drug, Humira The drug, which will lose patent protection in 2016, contributes 60% of Aberdeen's revenue Alberto didn't announce its acquisition of shire until Friday Now, Alberto plans to integrate its companies so that their effective tax rate is 13%, much lower than its current 22% This means that the acquisition will become the largest transaction to reduce corporate tax burden through M & A It is understood that Pfizer, the US pharmaceutical giant, adopted a similar strategy earlier this year when its US $118 billion acquisition of AstraZeneca in Sweden was rejected Shire's board of directors said on Monday that it had proposed to let Aberdeen offer a bid, which means the long-term negotiations between the two sides on the deal are over The offer represents a 53% premium to shire's share price on May 2, the time when the company first proposed a merger Shire shares rose 1.9% to £ 48.99 on Friday at 1027 GMT Shire holds a 25% stake in the post merger group